227
Participants
Start Date
May 10, 2021
Primary Completion Date
September 5, 2025
Study Completion Date
September 5, 2025
AB680
AB680 is a cluster of differentiated CD73 Inhibitor
Etrumadenant
Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Bevacizumab
Bevacizumab is administered as part of standard chemotherapy regimen
m-FOLFOX-6 regimen
mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
Regorafenib
Regorafenib is administered as part of standard chemotherapy regimen
Seoul National University Hospital (SNUH), Seoul
Samsung Medical Center, Seoul
Corporacio Sanitaria Parc Tauli, Sabadell
Korea University Anam Hospital, Seoul
NYU Langone Medical Center - NYU Medical Oncology Associates, New York
New York-Presbyterian Hospital-Columbia University Medical Center, New York
Seoul National University Bundang Hospital, Seoul
Istituto Clinico Humanitas IRCCS, Rozzano
Azienda Ospedaliera Niguarda Ca' Granda, Milan
Instituto Europeo di Oncologia, Milan
American Oncology Partners of Maryland PA, Bethesda
Centre Georges Francois Leclerc, Dijon
Hospital Universitario La Paz, Madrid
Hospital General Universitario Gregorio Maranon, Madrid
Prisma Health-Upstate, Greenville
Winship Cancer Institute at Emory University, Atlanta
Clinica Universidad Navarra-Sede Madrid, Pamplona
Complejo Hospitalario de Orense, Ourense
Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux
Vanderbilt-Ingram Cancer Center, Nashville
Sarah Cannon Research Institute, Nashville
Hopital Hotel Dieu, Nantes
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Florence
Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte, Siena
University of Wisconsin School of Medicine, Madison
Chonnam National University Hwasun Hospital, Hwasun
Washington University School of Medicine, St Louis
IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, Castellana Grotte
Ochsner Medical Center (OMC), New Orleans
Hopital Saint Antoine, Paris
Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite, Paris
The University of Texas MD Anderson Cancer Center, Houston
Arizona Clinical Research Center Inc, Tucson
CHU la Miletrie, Poitiers
Comprehensive Cancer Centers Of Nevada, Las Vegas
UCLA Hematology Oncology, Santa Monica
City of Hope Comprehensive Cancer Center, Duarte
Yale Cancer Center, New Haven
Sibley Memorial Hospital, Washington D.C.
"Severance Hospital , Yonsei University Health System"
"Asan Medical Center , University of Ulsan College of Medicine"
Kyungpook National University Chilgok Hospital, Seoul
Belfast City Hospital, Belfast
Aberdeen Royal Infirmary, Aberdeen
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY